Table 2 Study and patient characteristics of the included studies
Author | Year | Study characteristics | Patient characteristics | ||||||
|---|---|---|---|---|---|---|---|---|---|
Country | Study design | Analysis | Gold standard | Study duration | No. of patients | Mean age ± SD | Treatment received (no. of pts) | ||
Seto et al. [22] | 2022 | Japan | Retro | PB | Histopathology | 2017–2019 | 16 | NA | NA |
Catalano et al. [23] | 2021 | American | Retro | PB | Histopathology Image follow-up | 2016–2019 | 62 | 54 ± 12 | Surg(29),NAG + Surg(14),Cx/Cx + RTx(19) |
Crimì et al. [24] | 2020 | Italy | Pro | PB | Histopathology | 2015–2018 | 36 | 68.5 (43–89) | Surg + Cx + RTx |
Brendle et al. [25] | 2016 | Germany | Retro | LB | Image follow-up | NA | 15 | 45.0(10–62) | Surg(1),Cx(3),Surg + Cx(9),Surg + Cx + RTx(1),untreated(1) |
Kang et al. [13] | 2016 | Korea | Retro | PB | Histopathology | 2012–2013 | 12 | 60.2 (34–81) | Surg(12) |
Lee et al. [26] | 2015 | Korea | Pro | PB | Histopathology/image follow-up | 2013 | 20 | 58.3 ± 12.0 | Surg,NAG |
Li et al. [27] | 2020 | Germany | Retro | PB | Histopathology | 2012–2020 | 23 | NA | NA |